Trial Profile
A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2009
Price :
$35
*
At a glance
- Drugs XR 311 (Primary) ; Carboplatin; Carmustine; Cisplatin; Lomustine; Nimustine; Procarbazine; Temozolomide; Vincristine
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Xenova Group
- 13 Oct 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Oct 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Aug 2005 New trial record.